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Abstract
Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein
enzymes involved in DNA damage response and works by recognizing the single-strand DNA break (ssDNA) and
then effecting DNA repair. A double-strand DNA (dsDNA) break can be repaired by one of two different pathways:
homologous recombination (HR) or non-homologous end joining (NHEJ). Homologous recombination occurs in the
G2 or M phase of the cell cycle when a sister chromatid is available to use as a template for repair. Because a
template is available, HR is a high fidelity, error-free form of DNA repair. With NHEJ there is not a template and the
DNA is trimmed and ligated which is a very error-prone process of repair which can lead to genetic instability.
Exploiting these mechanism led to development of PARP inhibitors with the idea of utilizing synthetic lethality,
where two deficiencies each having no effect on the cellular outcome become lethal when combined, as single
agent in BRCA deficient patients or as chemotherapy/radiotherapy combinations to inhibit ssDNA repair. The recent
approval of olaparib in BRCA deficient ovarian cancer patients in US and Europe has opened up a whole new
treatment option for ovarian cancer patients. This review will discuss the different PARP inhibitors in development
and the potential use of this class of agents in the future.
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Background
Ovarian cancer is the leading cause of death from
gynecological malignancies in the United States with an
incidence rate of approximately 22,000 and 14,000
deaths per year. Despite all of the headway made in can-
cer overall, with a risk of dying from cancer decreasing
by 20 % since 1991, the relative 5-years survival rates of
ovarian cancer has remained poor 36 % in 1970’s and
still only 44 % in 2000’s and much worse in late stage
disease [1].
Cellular replication is a complex process which is the
way living organisms are able to grow and propagate.
Replication is a very controlled process with many points
of error detection and redundancy to ensure that a high
fidelity functioning copy of genetic material is main-
tained. Essential to this process is the unwinding of the
DNA from histone complexes and followed by the active
replication processes during S-phase, during this time
period DNA is very susceptible to environmental dam-
age or even errors in the replicative process itself [2].
There are a host of detection and repair mechanisms in
place which try to minimize errors, which lead to muta-
tions. The BRCA genes are a family of tumor suppressor
genes responsible for helping to protect the genome,
and the most widely known and studied with current
clinical importance are BRCA1 and BRCA2 [3]. BRCA1
is located on chromosome 17 and has many cellular
functions such as DNA repair, transcriptional regulation
and chromatin remodeling and BRCA2 is located on
chromosome 13 and is responsible for DNA recombin-
ation and repair primarily by chaperoning RAD51, the
enzyme responsible for facilitating recombination [4].
These two genes were described in 1994 and 1995 and
the repair pathways which they work have become clin-
ical targets for molecular therapies [5, 6]. Deficiencies in
these genes have been historically associated with her-
editary breast and ovarian cancer but they also increase
risk for uterine, cervical, colon, male breast, prostate,
pancreatic cancers, and melanoma [7].
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Poly(ADP-ribose) polymerase (PARP), which was first
described over 50 years ago by Mandel [8], works by rec-
ognizing the single-strand DNA break (ssDNA) and then
effecting DNA repair [9] through the base excisional
pathway (BER). The proteins consist of two ribose moi-
eties and two phosphates (Fig. 1), and DNA strand
breaks are responsible for activating the protein [10].
The PARP catalytic domain binds NAD+ via a unique pro-
tein fold, PARP-1 has a combination of zinc fingers and
PARP-2 and PARP-3 have different N-terminal domains
with very specific regulatory functions in mitotic segrega-
tion as well as basal metabolism [11, 12]. PARP is also in-
volved in methylation and transcription of genes coding
for cell cycle and stress response, including p53. PARP
Fig. 1 Mechanism of PARP. a Poly(ADP-ribose) polymerase 1 (PARP1) is shown with its DNA-binding (DBD), automodification (AD) and catalytic
domains. The PARP signature sequence (yellow box within the catalytic domain) comprises the sequence most conserved among PARPs. Crucial
residues for nicotinamide adenine dinucleotide (NAD+) binding (histidine; H and tyrosine; Y) and for polymerase activity (glutamic acid; E) are
indicated. b | Consequences of PARP1 activation by DNA damage. Although not shown to simplify the scheme, PARP1 is active in a homodimeric
form. PARP1 detects DNA damage through its DBD. This activates PARP1 to synthesize poly(ADP) ribose (pADPr; yellow beads) on acceptor proteins,
including histones and PARP1. Owing to the dense negative charge of pADPr, PARP1 loses affinity for DNA, allowing the recruitment of repair proteins
by pADPr to the damaged DNA (blue and purple circles). Poly(ADP-ribose) glycohydrolase (PARG) and possibly ADP-ribose hydrolase 3 (ARH3)
hydrolyse pADPr into ADP-ribose molecules and free pADPr. ADP-ribose is further metabolized by the pyrophosphohydrolase NUDIX enzymes into
AMP, raising AMP:ATP ratios, which in turn activate the metabolic sensor AMP-activated protein kinase (AMPK). NAD+ is replenished by the enzymatic
conversion of nicotinamide into NAD+ at the expense of phosphoribosylpyrophosphate (PRPP) and ATP. Examples of proteins non-covalently (pADPr-
binding proteins) or covalently poly(ADP-ribosyl)ated are shown with the functional consequences of modification. It is important to note that many
potential protein acceptors of pADPr remain to be identified owing to the difficulty of purifying pADPr-binding proteins in vivo. PARP inhibitors
prevent the synthesis of pADPr and hinder subsequent downstream repair processes, lengthening the lifetime of DNA lesions. ATM, ataxia
telangiectasia-mutated; BER, base excision repair; BRCT, BRCA1 carboxy-terminal repeat motif; DNA-PKcs, DNA-protein kinase catalytic
subunit; DSB, double-strand break; HR, homologous recombination; NHEJ, non-homologous end joining; NLS, nuclear localization signal;
PPi, inorganic pyrophosphate; SSB, single-strand break; Zn, zinc finger. Reprinted by permission from Macmillan Publishers Ltd: Nat Rev
Cancer, 2010,10(4):293–301, copyright (2010) [10]
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attaches DNA polymerase β to the DNA break site to re-
place the missing bases [10].
A double-strand DNA (dsDNA) break can be
repaired by one of two different pathways: homolo-
gous recombination (HR) or non-homologous end
joining (NHEJ). Homologous recombination occurs in
the G2 or M phase of the cell cycle when a sister
chromatid is available to use as a template for repair
[13]. Because a template is available, HR is a high fi-
delity, error-free form of DNA repair. With NHEJ
there is not a template and the DNA is trimmed and
ligated which is a very error-prone process of repair
which can lead to genetic instability [14]. In patients
that have BRCA deficient HR pathway the BER res-
cues the cell and leads to a viable cell [15]. When
PARP is inhibited in a HR deficient cell, e.g. BRCA
mutation, the ssDNA break is not repaired by either
the BER or HR pathway. [16]. Solid tumors carrying
various DNA repair defects have shown increased
sensitivity to PARP inhibitors or DNA-damaging che-
motherapies [17]. PARP inhibitors have shown activity
as monotherapy in cells deficient for the repair of
dsDNA breaks by HR as in case of BRCA deleterious
mutation cells showcasing the principle of synthetic
lethality. The concept of synthetic lethality is where
two deficiencies each having no effect on the cellular
outcome become lethal when combined. Cells which
are BRCA deficient and then undergo PARP inhib-
ition, leads to cell death [4].
PARP trapping is another recently described mechan-
ism by which PARP inhibitors are able to kill cancer
cells. PARP inhibitors trapped PARP1 and PARP2 to
the sites of DNA damage and then the PARP enzyme-
inhibitor complex locks onto the damaged DNA and
stops DNA repair, transcription, and replication which
then leads to cellular death [18]. Trapped PARP–DNA
complexes were more cytotoxic than unrepaired single
strand breaks (SSBs) caused by PARP inactivation,
Murai et al. suggested that PARP inhibitors act in part
as poisons that irreversibly trap PARP enzyme on DNA
[19]. The potency in trapping PARP differed markedly
among the PARP inhibitors in clinical development in a
pattern not correlated with the catalytic inhibitory prop-
erties [20]. Thirty genetically altered avian DT40 cell
lines with pre-established deletions in specific DNA re-
pair genes were analyzed to reveal that, in addition to
homologous recombination, post replication repair, the
Fanconi anemia pathway, polymerase β, and FEN1 are
critical for repairing trapped PARP–DNA complexes
[18, 19]. This suggest that other defects in the HR
pathway, including PTEN defects, Fanconi’s anemia pro-
tein defects, ATM abnormalities, RAD51 dysfunction,




The idea of synthetic lethality has led to the use of single
agent PARP inhibitors in BRCA deficient cancers.
Olaparib (AZD 2281) is an oral PARP inhibitor that has
shown activity in ovarian and breast tumors with known
BRCA mutations and was the first FDA approved drug
in this class [21]. The first hint of clinical activity in
BRCA mutation patients was seen in a phase I single
agent trial with 50 ovarian cancer patients with BRCA
mutations. Twenty patients had CR or PR by response
evaluation criteria in solid tumors (RECIST) and three
patients had been SD for longer than 4 months, result-
ing in a clinical benefit rate of 46 % (23/50). The median
duration of response was 28 months. The most common
drug related toxicities were fatigue and mild gastrointes-
tinal (GI) symptoms. A post analysis showed a statisti-
cally significant difference in response among platinum
sensitive, resistant, and refractory populations (61, 42,
and 15 %, respectively), though no differences were
noted in the duration of response or time to progression
between the three platinum response groups [22]. The
FDA approval of olaparib in advanced ovarian cancer as-
sociated with defective BRCA genes was partially based
on an international multicenter single-arm trail with 317
patients whom 193 had measurable germline BRCA mu-
tation ovarian cancer with a mean of 4.3 prior lines of
therapy and considered platinum resistant. They were
given 400 mg oral olaparib twice a day until progression
or toxicity. They showed an overall response rate of rate
of 31 % (95 % CI, 24.6 to 38.1), and stable disease (at
8 weeks) of 40 % (95 % CI, 33.4 to 47.7) along with a
median OS of 16.6 months [23].
PARP-1/2 inhibitors have been demonstrated to be ef-
fective in preclinical models in combination with plat-
inum, alkylating and methylation agents, topoisomerase
I inhibitors and radiation therapy [16]. In a phase I/Ib
trial of olaparib with carboplatin in germline BRCA mu-
tation breast/ovarian cancer patients with an expansion
cohort treated with 400 mg twice a day D 1–7 along
with carboplatin AUC 5 days one every 21 days followed
by maintenance of olaparib 400 mg twice a day until
progression showed an ORR of 52.4 %. Responses in-
cluded one complete response (one breast cancer;
23 months) and 21 partial responses (50.0 %; 15 ovarian
cancer; six breast cancer; median = 16 [4 to >45] in ovar-
ian cancer and 10 [6 to >40] months in breast cancer)
[24]. Olaparib was also combined with carboplatin and
paclitaxel in a study aimed to determine the safety of
olaparib in one of four dosing regimens: continuously
with carboplatin, continuously with paclitaxel, continu-
ously with both carboplatin and paclitaxel or intermit-
tently with the chemotherapy combination. Eighty seven
patients were enrolled, 12 of whom had known germline
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BRCA one or two mutations. AEs were primarily myelo-
toxicity (neutropenia and thrombocytopenia of any grade
occurring in 54 and 26 %, respectively). The dosing
schedules deemed tolerable were olaparib with weekly
paclitaxel (100 mg BD continuously and 80 mg/m2, re-
spectively) and intermittent olaparib with 3-weekly doses
of carboplatin and paclitaxel (200 mg BD d1-10 and
AUC4 with 175 mg/m2, respectively). Sixteen percent of
patients had an objective response and 28 % had stable
disease that persisted for at least 4 months. Greater effi-
cacy was evident in patients with BRCA mutations (two
complete and four partial responses) [25]. Oza con-
ducted a randomized phase II study, comparing six cy-
cles of carboplatin and paclitaxel with olaparib (olaparib
200 mg/m2 BID d1-10 & carboplatin AUC 4 D1 & pacli-
taxel 175 mg/m2 D1, over a 21 day cycle) followed by
maintenance olaparib (400 mg BID) until progression to
six cycles of carboplatin and paclitaxel alone (AUC 6
and 175 mg/m2 respectively both D1, over a
21 days cycle), in patients with advanced serous ovarian
cancer. The primary outcome, progression free survival,
significantly favored those patients receiving olaparib in
addition to chemotherapy (HR = 0.51, 95 % P = 0.0012)
increasing median survival from 9.6 to 12.2 months [26].
Olaparib with cisplatin and gemcitabine was evaluated
as a phase I trial by Rajan in advanced solid tumors.
They saw high rates of myelosuppression even at early
dose levels (DL1 olaparib 100 mg orally BID D1-4, gem-
citabine 500 mg/m2 D3 & 10, and cisplatin 60 mg/m2
D3) which prompted dose reductions. Of the 21 patients
which they evaluated two had PR. MTD was determined
to be olaparib 100 mg orally once daily on D1, gemcita-
bine 500 mg/m2 on D1 & 8, and cisplatin 60 mg/m2 on
D1. They were also able to demonstrate the olaparib
inhibited PARP in PBMC and tumor tissue although
they said that PARP levels were less efficiently inhibited
when it was used for a short duration based on their ob-
servations that maximum inhibition of PAR was seen be-
tween 6 and 24 h after the first dose of administration
and that PAR levels had started approaching baseline
values within 36 h of the last dose of olaparib and
exceeded baseline values in 80 % of cases before the next
cycle of treatment [27]. There are a number of ongoing
Phase I and II trials which various combinations cur-
rently underway and should have some promising results
based on early phase trials.
After a number of early trials help to solidify the
mechanism of action, the idea of maintenance therapy
was explored. A randomized, double-blind, placebo-
controlled study evaluated maintenance treatment with
olaparib in patients with platinum-sensitive, relapsed,
high-grade serous ovarian cancer who had received two
or more platinum-based regimens and had had a partial
or complete response to their most recent platinum-
based regimen. Two hundred sixty-five patients were
randomized 1:1 to 400 mg bid of olaparib vs placebo.
Their primary end point was progression-free survival.
Progression-free survival was significantly longer with
olaparib than with placebo (median, 8.4 months vs.
4.8 months from randomization at time of completion
of chemotherapy; hazard ratio for progression or death,
0.35; 95 % confidence interval [CI], 0.25 to 0.49; P <
0.001) Subgroup analyses of progression-free survival
showed that, regardless of subgroup, patients in the ola-
parib group had a lower risk of progression. The first in-
terim analysis of overall survival (38 % maturity) showed
no significant difference between groups (hazard ratio
with olaparib, 0.94; 95 % CI, 0.63 to 1.39; P = 0.75) [28].
At the second interim analysis, subgroup analysis was
included. BRCA status was known for 131 (96 %) pa-
tients in the olaparib group versus 123 (95 %) in the pla-
cebo group, of whom 74 (56 %) versus 62 (50 %) had a
deleterious or suspected deleterious germline or tumor
BRCA mutation. Of patients with a BRCA mutation, me-
dian PFS was significantly longer in the olaparib group
than in the placebo group (11.2 months [95 % CI 8.3-not
calculable] vs 4.3 months [3.0–5.4]; HR 0.18 [0.10–0.31];
p < 0.0001); similar findings were noted for patients with
wild-type BRCA, although the difference between treated
and placebo groups was lower (7.4 months [5.5–10.3] vs
5.5 months [3.7–5.6]; HR 0.54 [0.34–0.85]; p = 0.0075).
OS did not significantly differ between the groups (HR
0.88 [95 % CI 0.64–1.21]; p = 0.44); similar findings were
noted for patients with mutated BRCA (HR 0.73 [0.45–
1.17]; p = 0.19) and wild-type BRCA (HR 0.99 [0.63–1.55];
p = 0.96). The investigators concluded that these results
support the hypothesis that patients with platinum-
sensitive recurrent serous ovarian cancer with a BRCA
mutation have the greatest likelihood of benefiting from
olaparib maintenance therapy [29]. Moore presented two
AstraZeneca-sponsored Phase III trials of olaparib main-
tenance monotherapy in ovarian cancer patients with a
BRCA mutation: SOLO1 & SOLO2 at the 2014 ASCO
meeting. Both are double-blind multicenter studies in
which pts are being randomized (2:1) to receive olaparib
(300 mg [2 × 150 mg tablets] bid) or placebo SOLO1 is for
newly diagnosed patients and SOLO2 is for pretreated pa-
tients who have failed therapy. They have a planned ana-
lysis at ≈ 60 % maturity which is not available at time of
writing.
Angiogenesis inhibitors have been shown to be active
in recurrent ovarian cancer [30], and in vivo have been
tested with PARP inhibitors. In PARP-1 knockout mice
[31] the combination showed additive effects. Olaparib
was looked at with cediranib in a phase I trial and ap-
peared to improve PFS in women with recurrent
platinum-sensitive high-grade serous or endometrioid
ovarian cancer with hematologic DLT’s [32]. Sui looked
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at the combination of erlotinib and olaparib in EGFR-
overexpressing ovarian tumor xenografts. They were
able to show that erlotinib could slightly inhibit growth
of A2780 tumor xenografts but the combination treat-
ment had a markedly enhanced antitumor effect over
either agent alone. They showed that the antitumor ac-
tivity in BRCA-mutated xenograft models was 41 %
compared with 24 % in BRCA wild-type. Western blot
analysis revealed that treatment with erlotinib could sig-
nificantly reduce the phosphorylation level of ERK1/2
and AKT in A2780 tumor tissue. It was shown that the
autophagic effects were substantially enhanced when the
agents were combined, which they postulated may be
due to downregulation of apoptosis by decreasing p–p53
levels. Further investigations are underway to better
understand these processes [33].
Veliparib (abbvie)
Veliparib (ABT 888), in preclinical studies, was demon-
strated to be a strong inhibitor of PARP 1 and 2 and was
found to potentiate the effects of temozolomide, plat-
inum agents, cyclophosphamide, and radiation in syn-
geneic and xenograft tumor models. It was reported to
have good bioavailability and able to cross the blood–
brain barrier [34]. Based on these broad spectrums of
chemopotentiation and radiopotentiation further clinical
evaluation was undertaken.
Veliparib was combined with oral cyclophosphamide
in a phase II trial where adult patients with pretreated
BRCA-mutant ovarian cancer or primary peritoneal, fal-
lopian tube, or high-grade serous ovarian cancers
(HGSOC). The patients were randomized to receive
cyclophosphamide alone (50 mg orally once daily) or
with veliparib (60 mg orally once daily) in 21-day cycles,
crossover was allowed at disease progression. There
were 75 patients enrolled with 72 evaluable, 38
cyclophosphamide alone and 37 on the combination
arm. Of the 70 patients with responses one in each arm
had a CR. PR was seen in six patients in the
cyclophosphamide-only arm [7/36 (19.4 %) responses
overall; 95 % confidence interval (CI), 8.2–36.0 %] and
three patients in the combination arm [4/34 (11.8 %) re-
sponses overall; 95 % CI, 3.3–27.5 %], and one patient
who crossed over to the combination arm after progres-
sing on the cyclophosphamide-only arm. Overall the
addition of veliparib to cyclophosphamide did not im-
prove the response rate or the PFS over cyclophospha-
mide alone [35].
A phase II trial of veliparib was reported by Coleman
et al., looking at the clinical activity with use as a single
agent in ovarian cancer patients with a gBRCA1 or
gBRCA2 mutation. The eligibility criteria included pa-
tients with three or fewer lines of therapy none of which
would have been a PARPi. Veliparib was given at
400 mg orally twice a day for 28 day cycles. They re-
ported response of 26 % (90 % CI: 16–38 %, CR: 2, PR:
11); for platinum-resistant and platinum-sensitive pa-
tients the proportion responding was 20 and 35 %, re-
spectively. Overall 62 % were taken off study for
progression, 29 patients were alive at the end of study;
two with SD remained on veliparib and the median PFS
reported was 8.18 months [36].
Recently Veliparib has also been evaluated with whole
brain XRT for brain metastasis [37], combination with
temozolomide in metastatic melanoma [38], small cell
lung cancer with cisplatin and etoposide [39], as well as
whole abdominal radiation for peritoneal carcinomatosis
[40] all with promising results.
Rucaparib (Clovis)
Rucaparib (AG014699) was initially studied as a first in
class intravenous PARP inhibitor on an escalating dose
design with temozolomide. There were 33 patients en-
rolled with PARP inhibition seen in PBMC at all doses
through PK/PD studies with 74–97 % inhibition. The
combination was well tolerated and there were encour-
aging responses in patients including one complete re-
sponse and one partial response in melanoma, a partial
response in a desmoid tumor, seven patients with pro-
longed disease stabilization (~6 months) [41]. The on-
going ARIEL 2/3 trails were presented at ASCO 2014
and consisted of two parts: ARIEL2 (NCT01891344),
which is a Phase 2 trial of rucaparib trying to identify a
molecular HRD signature which would predict response
and Phase 3 ARIEL3 (NCT01968213), would then apply
this signature prospectively to the analysis of a similar
population. In ARIEL2, eligible patients (n = 180) who
have relapsed, platinum-sensitive HGOC and measur-
able disease will have a pre-dose biopsy and provide
archival tumor tissue. The design is then develop an ini-
tial HRD algorithm by using in vitro/in vivo and TCGA
(and similar) bioinformatics data from Foundation
Medicine’s NGS platform and Univ. of Washington’s
BROCA-HR panel. The algorithm will be designed to
correlate with tumor HRR status and PFS and response
(RECIST v1.1, GCIG CA-125). Then prospectively in
ARIEL3 (n = 540), optimized algorithm will then be
tested an ongoing, randomized (2:1), placebo-controlled
maintenance trial in platinum-sensitive HGSOC in re-
mission after platinum-based therapy. The primary end-
point of ARIEL3 is PFS in HRD subgroups determined
by NGS analysis of archival tumor tissue using the
ARIEL2 optimized algorithm[42], these studies at time
of manuscript writing are currently ongoing
Niraparib (tesaro)
Niraparib (MK4827) is another oral inhibitor of PARP1
and PARP2. It was tested in phase I trial as a single
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agent in advanced solid tumors, ovarian tumors, and
prostate tumors, and as combination therapy with car-
boplatin, with or without paclitaxel, and carboplatin with
liposomal doxorubicin in patients with advanced solid
tumors [43]. In a phase I trial of single agent niraparib
enriched with patients having BRCA1 or BRCA2 muta-
tions, six patients, including five with BRCA mutation,
achieved PR [44]. Niraparib has also been shown to be
an effective radiosensatizer especially in lung and breast
cancer cells [44, 45]. Additionally Tesaro is currently
sponsoring the Phase 2 QUADRA trial for patients with
heavily pretreated disease [46] as well as the NOVA trial
looking at maintenance in platinum sensitive disease
[47].
Talazoparib
Talazoparib (BMN 673) was designed as a potent novel in-
hibitor of PARP1 and PARP 2. Preclinical studies revealed
selective antitumor cytotoxicity and causes expression of
DNA repair biomarkers at much lower concentrations
than that of earlier generations of PARP1/2 inhibitors
[48]. Shen report that in vitro selectively targeted tumor
cells with BRCA1, BRCA2, or PTEN gene defects with
20–to more than 200–fold greater potency than existing
PARP1/2 inhibitors. BMN 673 is readily orally bioavailable
and in vivo xenografted tumors that carry defects in
BRCA or PTEN were profoundly sensitive to oral BMN
673 treatment. Synergistic or additive antitumor effects
were also found when BMN 673 was combined with tem-
ozolomide, SN38, or platinum drugs in xenograft models.
When evaluated in chicken DT40 cell lines, PALB2 muta-
tion predicts exceptional in vivo response to BMN 673
[49]. Further studies showed that the nanomolar cytotox-
icity is greater than that of rucaparib or olaparib and were
believed to be related to the trapping of PARP-DNA com-
plexes based on knockout mice models. All three drugs
appeared to be equally effective at inhibiting PARP cata-
lytic activity [50]. There are ongoing phase II trials in
ovarian and phase III in breast cancer (EMBRACA) [51].
Radiotherapy
PARP inhibitors enhance the effects of ionizing radiation
by means of inhibiting base excision repair and non-
homologous end joining as well as altered regulation of
cellular metabolism. [52] Both pre-clinical and clinical
data has shown an improvement in tumor response to
irradiation in the presence of PARP inhibitors. It had
been unclear if this benefit was due to changes in the re-
pair process or vasoactive effects contributing to tumor
re-oxygenation. The two questions that were asked was
if in S-phase the PARP inhibition increased the radio-
sensitivity of tumors and if at the tissue level it would
affect the microvasculature [53]. Hirai, et al., looked at
combination treatment with PARP inhibitors and single
fraction gamma-irradiation and showed that treatment
with a PARP inhibitor enhanced the cytotoxic effect of
gamma-irradiation. PARP inhibitor treatment induced S
phase arrest and enhanced subsequent G2/M arrest after
irradiation. These results suggest that the induction of S
phase arrest through an enhanced DNA Damage Re-
sponse (DDR) and a local delay in dsDNA break pro-
cessing by PARP inhibition caused sensitization to
irradiation [54].
Mechanisms of resistance
Multiple mechanisms of resistance to PARP inhibitors
therapy have been identified. Intrinsic resistance to ola-
parib was show by increased up regulation of P-
glycoprotein pumps in metaplastic breast carcinoma.
This is a common pharmacological effect that reduces
the efficacy of a number of drugs including PARP inhibi-
tors by effluxing the drugs out of the cell and thus redu-
cing the intracellular concentration of the drug available
for the therapy [55]. Because PARP inhibitors can
stabilize the cytotoxic PARP–DNA complexes, a loss-of-
function of PARP1 can potentially lead to 100 fold resist-
ance due to binding of PARP–DNA complexes and im-
paired catalytic inhibition of the PARP protein [56]. A
mouse model resistant to olaparib showed up-regulation
of a P-glycoprotein efflux pump caused by upregulating
of ABCb1 a/b gene. The resistance can be reversed by
inhibiting the pump with a P-glycoprotein inhibitor tari-
quidar [55]. Loss of 53BP1 leads to aberrant joining of
complex chromosome rearrangements in Brca1-deficient
cells by a process dependent on the non-homologous
end-joining factors 53BP1 and DNA ligase 4. Loss of
53BP1 alleviates hypersensitivity of BRCA1 mutant cells
to PARP inhibition and restores error-free repair by
homologous recombination. 53BP1 deletion promotes
ATM-dependent processing of broken DNA ends to
produce recombinant single-stranded DNA competent
for homologous recombination [57]. Another resistance
mechanism to PARP inhibitor therapy that has been
noted is via restoration of the homologous repair path-
way in BRCA targeted tumors. BRCA2 mutant patients
have shown resistance to PARP inhibitors by way of a
secondary mutation in the BRCA2 gene that restores the
open reading frame (ORF) which results in translation of
a functional BRCA2 protein [58]. PARP inhibitor-
resistant cells that up-regulation of NF-kappaB signaling
is was suggested as a key mechanism underlying ac-
quired resistance to PARP inhibition, and that NF-
kappaB inhibition, or bortezomib are potentially effective
anti-cancer agents after the acquisition of resistance to
PARP inhibitors [59]. These are some of the mechanistic
resistances to PARP inhibitors and more are being de-
scribed as this class of drug continues to be studied.
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Immunotherapy
Advances in immunotherapy have been at the forefront
of cancer development over the past few years with ex-
citing developments showing significant benefits to
patients. Combining DNA repair mechanisms with im-
mune based therapy offer new frontiers in clinical ad-
vancements. Preclinical data exists for combining
various PARPi with anti-CTLA-4, anti-PD1, as well as
anti-PDL1 but there is little clinical data at this time.
Higuchi looked at CTLA-4 blockade with PARPi ABT-
888(Veliparib) in BRCA1-deficient murine ovarian can-
cer models and showed that combination CTLA-4/
PARPi was able to provide therapeutic benefit in these
experiments supporting further clinical investigations
[60]. Trial NCT02571725 which is about to open will be
looking at combining olaparib with tremelimumab in
BRCA1/2 positive patients with recurrent ovarian cancer
[61]. Trial NCT02484404 at the NCI is enrolling to look
at novel anti-PDL1 (Durvalumab) in a Phase 1/2 in com-
bination either with olaparib or cediranib initially in re-
current solid tumor but then in recurrent ovarian, with
no data reported at this time [62]. At time of writing
there is recent announcement of a trial about to open
looking at combing niraparib and pembrolizumab in
BRCA-positive breast and ovarian patients. Immune
based therapies are breakthrough advancements in can-
cer care and combinations are appearing to offer prom-
ising results.
Future directions
The approval of olaparib in the maintenance setting
in Europe and metastatic setting in the US for pa-
tients with deleterious BRCA mutations in ovarian
cancer is just the tip of the iceberg for the utilization
for this class of agents. There are trials in progress to
address the additional populations that may have defi-
ciencies in the HR pathway that will benefit from
PARP inhibitors. Additionally, combination trials with
chemotherapy, radiation and TKIs are expanding the
exploration of usage. Suggested by the cediranib and
olaparib combination, combining PARP inhibitors
with anther agent may not require additional DNA
impairment for efficacy. Trials are also underway in-
vestigating agents that impair the DNA damage repair
pathway, like veliparib and dinaciclib creating syn-
thetic lethality without additional patient selection
[63]. With greater understanding of resistance mecha-
nisms, further trials utilizing combinations or sequen-
tial therapy to overcome the resistance to achieve
greater efficacy. The duration of administration espe-
cially in the maintenance setting will also need to be
considered to minimize resistance development. The
current ongoing immune based combinations trials
may bring additional synergistic efficacy and clinical
benefit. This is a new class of agent that has endless
possibilities for development and PARP inhibitors will
be an important tool in the fight against cancer.
Conclusions
PARP inhibitors is a new class of agents that have shown
activity in ovarian cancer. Activity in non BRCA muta-
tion related tumors are being explored both in ovarian
as well as outside of ovarian cancer. New combinations
with other targeted agents and immunotherapy will be
areas of great interest in the next few years.
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